DaVita (DVA) Q3 2026 Earnings Call Transcript
DaVita (DVA) Q3 2026 Earnings Call Transcript(摘要待生成)
DaVita Q3 Earnings Beat Estimates on IKC Strength, Revenues Rise Y/Y - Yahoo Finance
DaVita Q3 Earnings Beat Estimates on IKC Strength, Revenues Rise Y/Y - Yahoo Finance(摘要待生成)
DaVita 8-K (2.02, 9.01): reported results of operations
DaVita reported third-quarter 2026 revenue of $3.578 billion, operating income of $499 million, adjusted diluted EPS of $3.82 and operating cash flow of $519 million, and recorded a $62 million China-related impairment charge, reducing attributable net income by $27 million.
CorMedix Shares Decline Following DaVita Commentary on DefenCath Reimbursement
CorMedix shares reached a 52-week low after DaVita's CFO indicated that Medicare add-on payments for the DefenCath catheter lock solution are expected to decline significantly starting in the second quarter of 2027.
DaVita Inc. 3rd Quarter 2026 Results
DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter ended September 30, 2026. Financial and operating highlights for the quarter ended September 30, 2026:... The post DaVita Inc. 3rd Quarter 2026 Results appeared first on Investor.
Dialysis Giants DaVita and Fresenius Blocking Competition In Washington, Lawsuit Accuses - Benzinga
Dialysis Giants DaVita and Fresenius Blocking Competition In Washington, Lawsuit Accuses - Benzinga(摘要待生成)
DaVita Inc. to Participate in Upcoming Investor Conferences
DaVita Inc. (NYSE: DVA) today announced that its Chief Financial Officer, Joel Ackerman, and its Group Vice President of Investor Relations, Nic Eliason, will participate in fireside chats at the... The post DaVita Inc. to Participate in Upcoming Investor Conferences appeared first on Investor.
DaVita said DefenCath’s post-TDAPA reimbursement could fall significantly in 2027
On October 29, DaVita said the DefenCath post-TDAPA add-on payment is recalculated quarterly using volume and ASP, and its current expectation is that the amount will drop significantly from Q1 to Q2 2027, then remain low or decline through H2 2027. On October 30, CRMD fell 25.46% to $5.70, its 52-week low; the cited sources do not establish how much of the move was attributable to this warning.